MicroPort Scientific : Dongguan Kewei Attends 17th National Thoracic and Cardiovascular...

Hangzhou, China - From November 2 to November 4, Dongguan Kewei Medical Instrument Co., Ltd. ('Dongguan Kewei'), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ('MicroPort®'), attended the 17th National Thoracic and Cardiovascular Surgery Congress held in Hangzhou to host a satellite meeting and display its occluders and extracorporeal circulation products.

On November 4, Dongguan Kewei hosted a satellite meeting on 'the Application of EverMend™ Occluder in the Treatment of Congenital Heart Disease ('CHD')'. Director Weida Zhang of General Hospital of Guangzhou Military Command of PLA and Director Jianming Wang of Children's Hospital of Hebei Province were invited as co-chairmen of the meeting. Director Qi Xie of Fujian Provincial Hospital, Director Jian Zuo of the First Affiliated Hospital of the Fourth Military Medical University, Director Tao Ma of General Hospital of Guangzhou Military Command of PLA, and Director Junping Yao of Children's Hospital of Hebei Province were invited to deliver speeches respectively regarding 'the Surgical and Interventional Treatment of CHD with MicroPortOccluder,' 'Evaluation of EverMend™ Occluder Treatment Efficacy and Safety', 'Transthoracic Occlusion Technique and Complication Prevention', and 'Clinical Experience in EverMend™ Occluder'. Many of them spoke highly of Dongguan Kewei's EverMend™ Occluder for its high safety, low occurrence rate of complications, as well as excellent safety and short- and long-term efficacy.

The EverMend™ Occluder series include PDA, ASD, VSD and delivery systems. Compared to competitors in the market, EverMend™ has advantages in mesh frame, membrane of occluder and delivery systems. Its mesh frame adopts high-performance nitinol material, which features excellent hyperelasticity, resilience, and biocompatibility. Its waist uses patent fabric PET membrane and double-layered non-woven fabric, which has a better effect of blocking blood flow and tissue repair. Its delivery system is made of imported reinforced PTFE material to ensure the intensity and resilience of the sheath while achieving bigger inner diameter, making it easier for clinical operation.

During this meeting, experts exchanged ideas regarding the application of EverMend™ Occluder, and their excellent clinical performance and product quality further enhanced the experts' recognition in Dongguan Kewei's occluders, which is expected to help further promote the products so as to benefit more CHD patients.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]